ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 55 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $398,000 | -40.2% | 32,480 | -44.1% | 0.00% | -33.3% |
| Q2 2017 | $666,000 | -30.8% | 58,137 | +25.6% | 0.00% | -25.0% |
| Q1 2017 | $963,000 | -4.0% | 46,284 | -4.0% | 0.00% | 0.0% |
| Q4 2016 | $1,003,000 | -38.4% | 48,221 | -3.0% | 0.00% | -42.9% |
| Q3 2016 | $1,629,000 | +31.3% | 49,699 | 0.0% | 0.01% | +40.0% |
| Q2 2016 | $1,241,000 | +48.8% | 49,699 | +48.0% | 0.01% | +25.0% |
| Q1 2016 | $834,000 | -16.8% | 33,573 | +10.5% | 0.00% | 0.0% |
| Q4 2015 | $1,003,000 | +105.1% | 30,380 | +103.6% | 0.00% | +100.0% |
| Q3 2015 | $489,000 | -30.8% | 14,923 | +11.9% | 0.00% | -33.3% |
| Q2 2015 | $707,000 | +230.4% | 13,339 | +79.9% | 0.00% | +200.0% |
| Q1 2015 | $214,000 | +18.2% | 7,413 | +19.4% | 0.00% | 0.0% |
| Q4 2014 | $181,000 | +129.1% | 6,209 | 0.0% | 0.00% | – |
| Q3 2014 | $79,000 | -35.2% | 6,209 | +2.1% | 0.00% | – |
| Q2 2014 | $122,000 | – | 6,079 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,130 | $34,629,000 | 11.36% |
| Foresite Capital Management II, LLC | 1,586,220 | $18,670,000 | 10.50% |
| DAFNA Capital Management LLC | 636,013 | $7,486,000 | 2.81% |
| Redmile Group, LLC | 8,244,896 | $97,042,000 | 2.75% |
| Lion Point Capital, LP | 1,204,600 | $14,178,000 | 1.40% |
| Palo Alto Investors LP | 1,861,630 | $21,911,000 | 1.06% |
| SAMLYN CAPITAL, LLC | 3,517,856 | $41,405,000 | 0.87% |
| Bellevue Group AG | 4,118,806 | $48,478,000 | 0.83% |
| Rock Springs Capital Management LP | 1,562,300 | $18,388,000 | 0.66% |
| Artal Group S.A. | 850,000 | $10,005,000 | 0.40% |